Expertise in
9
conditions
Expertise in
9
conditions
282 Washington St, 
Hartford, CT 

Overview

Michael Isakoff is a Hematologist and an Oncologist in Hartford, Connecticut. Dr. Isakoff has been practicing medicine for over 27 years is highly rated in 9 conditions, according to our data. His top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Isakoff is currently accepting new patients.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 74 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

New York University School Of Medicine, 1999

Residency

Yale-New Haven Hospital

Specialties

Hematology
Oncology
Pediatrics

Licenses

Pediatric Hematology-Oncology in CT

Board Certifications

American Board Of Pediatrics, Pediatric Hematology & Oncology, Pediatric Hematology Oncology
American Board Of Pediatrics

Fellowships

Boston Children's Hospital Neonatal Perinatal Fellowship Program

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

CCMC - Hematology
282 Washington St, Hartford, CT 06106

Additional Areas of Focus

Dr. Isakoff has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


74 Clinical Trials

Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
View 46 Less Clinical Trials
Similar Doctors
Expertise in
8
conditions
Hematology | Oncology
Expertise in
8
conditions
Hematology | Oncology

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (33.7 miles away)
Languages Spoken:
English

Farzana Pashankar is a Hematologist and an Oncologist in New Haven, Connecticut. Dr. Pashankar is highly rated in 8 conditions, according to our data. Her top areas of expertise are Germ Cell Tumor, Teratoma of the Mediastinum, Sickle Cell Disease, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
49
conditions
Hematology | Oncology
Expertise in
49
conditions
Hematology | Oncology

Hartford Healthcare Medical Group

339 W Main St, 
Avon, CT 
 (10.1 miles away)
Languages Spoken:
English
Offers Telehealth

Todd Alekshun is a Hematologist and an Oncologist in Avon, Connecticut. Dr. Alekshun is highly rated in 49 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Lung Adenocarcinoma.

Expertise in
14
conditions
Hematology | Oncology
Expertise in
14
conditions
Hematology | Oncology

Saint Vincent Medical Group-Eaton Place Oncology

1 Eaton Pl Ste 23, 
Worcester, MA 
 (57.2 miles away)
Languages Spoken:
English
Offers Telehealth

Archana Agarwal is a Hematologist and an Oncologist in Worcester, Massachusetts. Dr. Agarwal is highly rated in 14 conditions, according to our data. Her top areas of expertise are Hereditary Pyropoikilocytosis, Hereditary Spherocytosis, Hereditary Elliptocytosis, Hereditary Ovalocytosis, and Splenectomy.

Frequently Asked Questions about Dr. Michael Isakoff

How do I make an appointment with Dr. Michael Isakoff?

You can book an appointment with Dr. Michael Isakoff by calling their office at 860-545-9630. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael Isakoff a top-rated expert for Osteosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael Isakoff is classified as an Distinguished expert for Osteosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael Isakoff specialize in?

While Dr. Michael Isakoff is a Hematology, they have specific expertise in Osteosarcoma, Adult Soft Tissue Sarcoma, and Ewing Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Michael Isakoff participate in research or clinical trials?

Yes. Dr. Michael Isakoff has published 43 articles and abstracts on conditions like Osteosarcoma. You can view a list of Dr. Michael Isakoff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael Isakoff accept my insurance?

Dr. Michael Isakoff accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 860-545-9630 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Isakoff's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile